A Software Platform for Sensor-based Movement Disorder Recognition

 描述（由申请方提供）：本II期的目标是通过开发一种基于传感器的自动化方法来跟踪日常生活中无脚本活动期间广泛运动障碍的存在和严重程度，从而提高高级大脑和行为研究工具的可用性[PA-14-250]。持续更新和解释的信息从身体佩戴传感器将提供准确，客观，高分辨率（1秒）。帕金森病中震颤、运动障碍、运动迟缓、冻结和步态障碍的运动症状严重程度的测量以及特发性震颤中姿势性/运动性震颤的测量。它将使研究人员能够评估运动障碍的复杂性和动态性，这是目前自我报告和纸和纸工具的标准所无法捕捉的。可穿戴传感器技术的进步已经促进了这样的解决方案，但是目前没有运动障碍识别设备能够针对美国超过4500万患有运动障碍的人以有效的方式解释来自非脚本活动的传感器数据。我们的方法是独特的，因为我们正在开发一个通用的应用程序生成器（AG）软件平台，其中包含信号处理模块，可以很容易地配置为提供自动识别不同的疾病，而不需要从头开始为每个准备单独的算法。第一阶段通过开发一个基本的AG平台建立了概念验证，该平台通过新型混合传感器实现了帕金森病（PD）患者震颤，运动障碍和步态冻结的自动识别，该传感器通过表面肌电图（sEMG）和加速度计记录提供肌肉活动和运动数据。第二阶段将继续发展，包括更广泛的PD运动障碍，以及其他神经系统疾病。Aim 1将通过结合sEMG和惯性测量单元（IMU）传感器创建一个增强的AG平台，以更完整地描述非自主运动，并在跟踪其他疾病时降低风险。人体受试者测试将提供传感器数据库，用于测试IMU传感器准确性并最大限度地减少软组织伪影。第一阶段的识别算法将使用增强的平台进行更新。Aim 2将使用增强的平台开发新的识别应用程序，跟踪PD中的运动迟缓和步态障碍，以及原发性震颤患者的姿势和动力震颤。我们的目标是在不受约束的监测条件下，使用用户独立的算法实现错误率< 5%。Aim 3将提供一种便携式预商用设备，配备必要的硬件、软件、用户界面和报告生成器，以有效监测PD、特发性震颤和坐/站/步行活动。该系统将使用平板电脑收集和处理sEMG/IMU数据，以增强可用性。运动障碍专家和潜在的最终用户将指导II期开发，并协助我们制定其他神经系统疾病的未来商业化计划，如脑瘫，肌张力障碍，ALS和不宁腿综合征。它也将成为患者可操作的基础。 临床使用的器械。

 DESCRIPTION (provided by applicant): The goal of this Phase II is to enhance the availability of advanced brain and behavior research tools [PA-14-250] by developing an automated sensor-based means of tracking the presence and severity of a broad spectrum of movement disorders during unscripted activities of daily living. The continuously updated and interpreted information from body-worn sensors will provide accurate, objective, and high resolution (1 s.) measurement of motor symptom severity of tremor, dyskinesia, bradykinesia, freezing and gait disorders in Parkinson's disease and postural/kinetic tremor in essential tremor. It will allow researchers to assess the oftentimes complex and dynamic nature of movement disorders, which is poorly captured by the current standard of self-reports and pencil-and-paper instruments. Advances in wearable sensor technology have facilitated such a solution, but there are currently no movement disorder recognition devices capable of interpreting sensor data from non- scripted activity in an effective manner for the more than 45 million people in the U.S. with movement disorders. Our approach is unique in that we are developing a generic Application Generator (AG) software platform containing signal processing modules that can be readily configured to provide automated recognition for different disorders without the need to prepare separate algorithms from scratch for each. Phase I established a proof of concept by developing a rudimentary AG platform that achieved automatic recognition of tremor, dyskinesia and freezing-of-gait in patients with Parkinson's disease (PD) from novel hybrid sensors that provided both muscle activity and movement data through surface electromyographic (sEMG) and accelerometer recordings. Phase II will continue the development to include a broader range of PD movement disorders, as well as other neurological conditions. Aim 1 will create an enhanced AG Platform by incorporating combined sEMG and inertial measurement unit (IMU) sensors to more completely describe involuntary movements and reduce the risk when tracking additional disorders. Human subject testing will provide a sensor database for testing IMU sensor accuracy and minimizing soft tissue artifacts. The Phase I recognition algorithms will be updated using the enhanced platform. Aim 2 will use the enhanced platform to develop new recognition applications that track bradykinesia and gait disorders in PD, and postural and kinetic tremors in patients with essential tremor. Our goal is to achieve error rates < 5% during unconstrained monitoring conditions with user- independent algorithms. Aim 3 will deliver a portable pre-commercial device with the requisite hardware, software, user interface, and report generator to effectively monitor PD, essential tremor, and sitting/standing/walking activity. The system will collect and process sEMG/IMU data using a tablet PC to enhance usability. Movement disorder experts and prospective end-users will guide the Phase II development and assist us with future commercialization plans for other neurological conditions such as cerebral palsy, dystonia, ALS, and restless leg syndrome. It will also form the basis for a patient-operable device for clinical use.